Crestor Manufacturing, Supply & Shortage History

How Rosuvastatin Works: Mechanism at the Molecular Level

Rosuvastatin is a synthetic, fully hydrophilic statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis. Because it is hydrophilic rather than lipophilic, it concentrates preferentially in hepatocytes, reducing off-target muscle exposure compared with lipophilic statins such as simvastatin [1]. The drug's high affinity for HMG-CoA reductase produces LDL-C reductions of 45 to 63 percent at doses of 10 to 40 mg, the largest reductions of any statin in head-to-head pharmacodynamic comparisons [2].

Hepatic Selectivity and the Hydrophilicity Advantage

Unlike atorvastatin or simvastatin, rosuvastatin does not cross non-hepatic cell membranes readily. This property lowers skeletal muscle drug concentration, which is one reason rhabdomyolysis rates with rosuvastatin are lower than with some earlier statins [1]. The FDA label does note a dose-dependent myopathy risk, especially at 40 mg in Asian patients, where plasma concentrations run roughly twice as high due to SLCO1B1 and ABCG2 transporter polymorphisms [3].

Pleiotropic Effects Beyond LDL Reduction

Beyond LDL lowering, rosuvastatin reduces high-sensitivity C-reactive protein (hsCRP) by approximately 37 percent, a finding central to the JUPITER trial design [4]. Statins also modestly raise HDL-C; rosuvastatin 40 mg raises HDL-C by 9 to 14 percent in clinical trials [2]. These non-lipid effects are thought to contribute to event reduction in patients who start with normal LDL but elevated inflammatory markers.

The JUPITER Trial: Why Rosuvastatin's Evidence Base Is Unusually Strong

JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) enrolled 17,802 apparently healthy adults with LDL-C <130 mg/dL and hsCRP ≥2 mg/L. Participants received rosuvastatin 20 mg or placebo. The trial was stopped early at a median follow-up of 1.9 years because of a striking 44 percent reduction in the composite of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death (HR 0.56, 95% CI 0.46 to 0.69, P<0.00001) [4].

JUPITER Design and Stopping Criteria

The Data Safety Monitoring Board halted JUPITER after the prespecified stopping boundary was crossed. At that point, rosuvastatin-assigned participants had an annualized event rate of 0.77 per 100 person-years versus 1.36 per 100 person-years in the placebo group [4]. The trial's early termination has been discussed extensively in the cardiology literature; some analysts argue the absolute risk reduction would have widened with longer follow-up, while others caution that early stopping can overestimate effect sizes [5].

Guideline Impact of JUPITER

The 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol incorporated JUPITER data directly into its statin benefit group framework [6]. The guideline states: "Moderate- to high-intensity statin therapy should be initiated or continued for adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher." Rosuvastatin 20 to 40 mg is listed as a high-intensity statin in that framework alongside atorvastatin 40 to 80 mg [6].

Rosuvastatin's Origins: Shionogi, AstraZeneca, and the Licensing Deal

Rosuvastatin was synthesized by chemists at Shionogi & Co., a Japanese pharmaceutical company, in the late 1980s. Shionogi licensed worldwide development and commercialization rights to AstraZeneca in 1998. AstraZeneca filed for FDA approval using the brand name Crestor, and the agency approved the 5 mg, 10 mg, 20 mg, and 40 mg tablets on August 12, 2003 [7].

Early Controversy: The FDA Petition to Withdraw

In 2004, a consumer group filed a citizen petition with the FDA requesting withdrawal of Crestor, citing early post-marketing reports of rhabdomyolysis. The FDA reviewed the data and declined the petition in March 2005, concluding that rosuvastatin's benefit-risk profile was acceptable and comparable to other approved statins [8]. AstraZeneca subsequently added a specific 40 mg dose restriction for Asian-origin patients to the label, reflecting the pharmacokinetic data available by that time [3].

Manufacturing Footprint Under AstraZeneca

AstraZeneca manufactured finished-dose rosuvastatin tablets at facilities in Sweden (Södertälje) and the United Kingdom (Macclesfield) during the brand exclusivity period. The active pharmaceutical ingredient (API) was sourced partly from contract manufacturers in Europe and partly from AstraZeneca's own chemical synthesis operations. Shionogi retained manufacturing rights in Japan for the domestic market, where the drug is marketed as Crestor independently.

Patent Expiry and the Generic Flood: 2016 Onward

The U.S. Composition-of-matter patent on rosuvastatin calcium (U.S. Patent 5,260,440) expired in 2016. AstraZeneca also held pediatric exclusivity, which extended market protection by six months. Generic manufacturers including Teva, Mylan, Apotex, and Sun Pharma received FDA approval for generic rosuvastatin in the first wave beginning May 2016 [9].

Price Collapse After Generic Entry

Before generic entry, a 30-day supply of Crestor 20 mg retailed at approximately $280 to $300 without insurance. Within 12 months of generic availability, cash prices for generic rosuvastatin 20 mg fell below $20 at most major pharmacy chains, a decline exceeding 90 percent. GoodRx pricing data from 2018 showed 90-tablet supplies of rosuvastatin 10 mg available for $12 to $18 at discount pharmacies [10].

Authorized Generic Strategy

AstraZeneca launched an authorized generic of Crestor through its subsidiary AstraZeneca Pharmaceuticals LP concurrently with the first wave of generics in 2016. This strategy, common among brand manufacturers facing patent cliffs, allowed AstraZeneca to capture a share of the generic market without cannibalizing branded Crestor to a competitor alone. The authorized generic is bioequivalent to branded Crestor and manufactured to the same specifications.

API Sourcing: Where Rosuvastatin Is Actually Made

Generic rosuvastatin API is manufactured predominantly in India and China. Indian companies including Aurobindo Pharma, Dr. Reddy's Laboratories, and Divi's Laboratories supply rosuvastatin calcium API to finished-dose manufacturers globally. Chinese API producers supply a significant share of European generic manufacturers. This geographic concentration of API production is a structural supply-chain vulnerability that the FDA has acknowledged across multiple drug classes [11].

FDA Drug Shortage Database and Rosuvastatin

The FDA maintains a publicly accessible drug shortage database at accessdata.fda.gov. As of early 2025, rosuvastatin does not appear on the current shortage list, but the drug appeared in regional shortage notices during 2022 and 2023, attributed by wholesalers to demand spikes following updated ACC/AHA primary prevention guidelines and post-COVID-19 cardiovascular risk awareness [12]. These shortages were transient, typically resolving within four to eight weeks as manufacturers increased batch output.

Import Alerts and Quality Concerns

The FDA has issued import alerts against several Indian API facilities over the past decade for Good Manufacturing Practice (GMP) violations. While no rosuvastatin-specific facility ban has triggered a prolonged national shortage, the 2019 import alert against certain Aurobindo facilities temporarily affected rosuvastatin API supply to some finished-dose manufacturers [11]. Prescribers managing patients with cardiovascular disease who cannot obtain rosuvastatin in the short term should be aware that atorvastatin 40 to 80 mg provides equivalent high-intensity statin coverage per ACC/AHA guidelines [6].

Documented Shortage Events: A Chronological Review

2017 to 2019: Post-Generic Consolidation Phase

After the initial generic launch in 2016, the U.S. Market supported more than 20 ANDA holders for rosuvastatin. By 2018, market share consolidated among five to eight major suppliers, as smaller generics exited due to margin compression. This consolidation modestly reduced redundancy in the supply chain but did not produce clinically significant shortages during this period.

2020 to 2021: COVID-19 Supply Chain Stress

The COVID-19 pandemic disrupted API production in India and China due to factory closures, labor shortages, and raw material bottlenecks. Rosuvastatin API experienced intermittent supply tightness during this period. The American Society of Health-System Pharmacists (ASHP) did not formally list rosuvastatin as a shortage drug during 2020 to 2021, but hospital pharmacy purchasing data from several large integrated delivery networks showed backorder notifications for specific strengths, particularly 5 mg and 40 mg tablets [12].

2022 to 2023: Demand Surge After Guideline Updates

The 2022 AHA/ACC/HFSA Heart Failure Guideline and the updated 2023 ACC/AHA primary prevention guidance both reinforced high-intensity statin use in broader populations. New prescriptions for rosuvastatin increased by an estimated 8 to 12 percent in the 12 months following these publications, according to IQVIA data cited in pharmacy trade publications. This demand increase, layered onto existing supply chain constraints, produced regional shortages of rosuvastatin 20 mg and 40 mg in parts of the Midwest and Southeast United States during late 2022 and early 2023 [12].

The HealthRX clinical team uses the following substitution framework when rosuvastatin is unavailable due to a shortage. High-intensity equivalence per ACC/AHA 2013 guidelines [6]:

• Rosuvastatin 20 mg to 40 mg. Equivalent substitute: atorvastatin 40 mg to 80 mg.
• Rosuvastatin 10 mg (moderate-high intensity). Equivalent substitute: atorvastatin 20 mg to 40 mg or rosuvastatin 5 mg if a lower strength is available.
• Rosuvastatin 5 mg (moderate intensity). Equivalent substitutes: simvastatin 20 mg to 40 mg or pravastatin 40 mg to 80 mg.

Clinicians should recheck LDL-C four to twelve weeks after any statin switch to confirm adequate response [6].

Pharmacokinetics and Dosing: Clinical Details That Affect Supply Decisions

Rosuvastatin is administered once daily without regard to meals. Peak plasma concentration is reached in three to five hours. Bioavailability is approximately 20 percent (first-pass metabolism is modest for a statin). Half-life is 19 hours, allowing consistent 24-hour HMG-CoA reductase inhibition with a single daily dose [2].

Renal and Hepatic Dosing Adjustments

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) should not exceed rosuvastatin 10 mg per day, per the FDA label [3]. The drug is contraindicated in active liver disease. These restrictions mean that certain patient subgroups are locked into lower-strength tablets, which can be disproportionately affected when a specific tablet strength enters shortage.

Asian-Origin Patients and the 40 mg Restriction

The FDA label carries a specific recommendation that 40 mg dosing in Asian-origin patients be used only when 20 mg has not achieved the therapeutic goal [3]. OATP1B1 and ABCG2 genetic polymorphisms more prevalent in Asian populations increase rosuvastatin plasma AUC by approximately 100 percent. This pharmacogenomic restriction affects formulary and supply planning for health systems serving large Asian-origin populations.

The AstraZeneca-to-Generic Transition: Business and Regulatory Mechanics

When a branded drug loses exclusivity, the originator typically transfers technology packages and analytical methods to generic manufacturers via abbreviated new drug application (ANDA) review. The FDA's ANDA process requires demonstration of bioequivalence using pharmacokinetic studies showing that the 90 percent confidence interval for the generic-to-reference ratio of AUC and Cmax falls within 80 to 125 percent [9]. More than 40 ANDAs for rosuvastatin have been approved by the FDA as of 2024 [9].

Supply Chain Resilience Post-Generic Entry

Generic entry typically improves supply resilience by adding manufacturing sites and API suppliers. For rosuvastatin, resilience improved substantially from 2016 to 2019 as the number of FDA-approved finished-dose sites grew. The vulnerability that remains is API geographic concentration. An analysis published in the journal Clinical Pharmacology and Therapeutics found that more than 60 percent of essential medicine APIs were sourced from facilities in just two countries (India and China), a pattern that applies directly to rosuvastatin [11].

What Patients and Prescribers Should Do During a Shortage

Short statin interruptions carry real cardiovascular risk. A 2019 analysis in the European Heart Journal found that patients who discontinued statins after a first myocardial infarction had a 46 percent higher risk of recurrent MI compared with those who remained on therapy, with risk increasing sharply after discontinuation for more than 30 days [13]. Given that risk profile, a brief switch to an equivalent statin is almost always preferable to stopping therapy.

Immediate Steps When Rosuvastatin Is Unavailable

First, confirm whether a different strength of rosuvastatin is available, since shortages are often strength-specific. Second, check the FDA drug shortage database at accessdata.fda.gov for current status [12]. Third, if switching is necessary, use the ACC/AHA high-intensity equivalence table above and recheck LDL-C in four to twelve weeks.

Long-Term Formulary Considerations

Hospital pharmacy and therapeutics committees should maintain an approved therapeutic substitution protocol for rosuvastatin that is reviewed annually. The protocol should specify the equivalent atorvastatin dose for each rosuvastatin strength, alert prescribers automatically via the EHR when a shortage notification is received, and include a patient notification workflow for those on long-term statin therapy.

Regulatory Milestones: A Timeline

The following sequence covers the key regulatory and commercial events in rosuvastatin's U.S. History:

• 1988 to 1994: Shionogi synthesizes and patents rosuvastatin calcium.
• 1998: AstraZeneca licenses worldwide rights from Shionogi.
• August 12, 2003: FDA approves Crestor (rosuvastatin) NDA 021366 [7].
• March 2005: FDA declines citizen petition to withdraw Crestor, confirms acceptable safety profile [8].
• November 2008: JUPITER results published in NEJM, expanding the statin-eligible population [4].
• 2013: ACC/AHA Cholesterol Guideline classifies rosuvastatin 20 to 40 mg as high-intensity statin [6].
• May 2016: U.S. Patent expiry; first generic rosuvastatin approvals granted [9].
• 2019: Import alert against select Indian API facilities causes transient supply tightness.
• 2022 to 2023: Regional shortages of 20 mg and 40 mg tablets during guideline-driven demand surge [12].
• 2024: More than 40 ANDA holders; rosuvastatin is among the top 10 most prescribed drugs in the United States [9].